Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in ...

Jayme Locke, MD MARCO ISLAND, Fla.—The transplant community may want to rethink the importance of HLA mismatches when considering live donor kidney transplants, according to new data presented here at ...

HLA matching in bone marrow transplantation has an important role in determining successful outcome. However HLA typing of both potential related and unrelated donors can be both time-consuming and ...

DENVER—Kidney transplants involving living related and unrelated donors have similar 10-year graft survival, even with differences in HLA matching, according to Brazilian investigators. The ...

Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform ...

Post-transplantation cyclophosphamide (PTCy) led to similar overall survival (OS) and graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) in patients who received a hematopoietic stem ...

Please provide your email address to receive an email when new articles are posted on . Patients who received stem cell grafts from unrelated donors matched at as few as 4/8 HLA markers achieved ...

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors The study included 17,292 unrelated ...

Researchers at the University of Pittsburgh have identified a new way of predicting whether a kidney donor and recipient are a good match for transplantation. The findings, published today in Science ...